title: Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
abstract: BACKGROUND
  Fluorouracil (5-FU), oxaliplatin and irinotecan combinations improve time to tumor progression (TTP), objective response and overall survival (OS) in patients with metastatic colorectal cancer (MCRC). Here we identify and describe patients treated on Intergroup study N9741 who initially had inoperable MCRC, but who obtained sufficient chemotherapeutic benefit to allow removal of their metastatic disease.
  
  
  METHODS
  Patient research records in study arms (A) irinotecan/5-FU/leucovorin (LV) (IFL, n = 264), (F) oxaliplatin/5-FU/LV (FOLFOX4, n = 267) and (G) oxaliplatin/irinotecan (IROX, n = 265) were reviewed. TTP and median OS were calculated.
  
  
  RESULTS
  Twenty-four (3.3%) of 795 randomized patients underwent curative metastatic disease resection [hepatectomy, 16; radiofrequency-ablation (RFA), six; lung resection, two]. Twenty-two out of 24 (92%) resected patients received an oxaliplatin-based regimen (FOLFOX4, 11; IROX, 11). Seven patients (29.2%) remain disease-free; relapses occurred mainly in the resected organ. Median OS in resected patients is 42.4 months, and median TTP is 18.4 months. All six patients treated with RFA have recurred. Four out of five (80%) patients who received chemotherapy following resection are disease-free.
  
  
  CONCLUSIONS
  Resection of metastatic disease after chemotherapy is possible in a small but important subset of patients with MCRC, particularly after receiving an oxaliplatin-based chemotherapy regimen, with encouraging OS and TTP observed in these highly selected patients.
authors.affiliation: Department of Oncology, Cancer Center Statistics, Mayo Clinic, 200 First St Southwest, Rochester, MN 55905, USA.
authors.forename: T
authors.initials: T
authors.lastname: Delaunoit
authors.forename: S R
authors.initials: SR
authors.lastname: Alberts
authors.forename: D J
authors.initials: DJ
authors.lastname: Sargent
authors.forename: E
authors.initials: E
authors.lastname: Green
authors.forename: R M
authors.initials: RM
authors.lastname: Goldberg
authors.forename: J
authors.initials: J
authors.lastname: Krook
authors.forename: C
authors.initials: C
authors.lastname: Fuchs
authors.forename: R K
authors.initials: RK
authors.lastname: Ramanathan
authors.forename: S K
authors.initials: SK
authors.lastname: Williamson
authors.forename: R F
authors.initials: RF
authors.lastname: Morton
authors.forename: B P
authors.initials: BP
authors.lastname: Findlay
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D017115:Catheter Ablation; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D018579:Patient Selection; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin